Topic
Description
1
Main active ingredient
Polymethylsiloxane polyhydrate (PMSPH)
2
Physicochemical properties
Enterosgel does not interact with the mucous membrane, it does not damage the mucous lining. Enterosgel forms spatial cross-linked large globules of methyl group. The Enterosgel molecule surface is hydrophobic. Enterosgel is not absorbed by the body tissues.
3
Detoxifying properties
Enterosgel adsorbs toxic substances from the gastrointestinal tract and decreases their levels in the body. Toxic substances and metabolites are excreted into the small intestinal lumen in a form of complexes and afterwards undergo re-adsorption.  In the intestinal lumen  Enterosgel absorbs toxic substances and prevents their reverse absorption.
4
Peculiarities of sorption  (sorption selectivity
Enterosgel absorbs and eliminates predominantly toxic substances with intermediate molecular weights, toxic metabolites, and protein degradation products (indole, cadaverine, etc.), as well as products of incomplete metabolism.
It does not bind beneficial substances (micronutrients, vitamins, amino acids) and does not cause deficiency of vital substances.
Has low activity towards drug substances.
There were no reports on reduction of the therapeutic effects of the other medications during their use in combination with Enterosgel. Observations have demonstrated that Enterosgel improves therapeutic efficacy when used in complex treatment of various diseases.
5
Radionuclides elimination
Two-week treatment with Enterosgel results in elimination of up to 95 % of radionuclides from the blood circulation. Along with the radionuclides  Enterosgel carries away from the body other harmful substances that accumulate under the action of radiation (including ionizing radiation) - radiotoxins, peroxides, quinones.
6
Peculiarities of the effects on microflora
Enterosgel destroys pathogenic microorganisms and eliminates exo- and endotoxins produced by the microorganisms during their life activity and death. Enterosgel promotes adjustment of microbiocenosis .
Pathogenic bacteria possess active adhesive properties. They are destroyed as a result of electrostatic interaction with Enterosgel.
Normal microflora forms a structural part of the mucous membrane. Therefore it lives in a more comfortable environment, secured by mucus overlays and, thus, not destroyed by Enterosgel. Enterosgel is hydrophobic and does not enter the epithelial layer of the mucous membrane.
Enterosgel-induced regeneration of the epithelial layer of the intestinal barrier and enhancement of the immune defense of the intestinal barrier results in restoration of colonization resistance of the mucous membrane.
7
Mucous membrane regeneration
Enterosgel exerts cytoprotective properties. It protects the mucous membrane from chemical and mechanical damage. Enterosgel restores the mucous membrane and the process of regeneration, microcirculation and physiological mucus production. It promotes recovery of the immune protection of the mucous membrane and normalizes concentrations of secretory immunoglobulin А.
Enterosgel sorbs and eliminates products of microbial metabolism and their toxic components:
- substances damaging the intestinal mucous membrane (deconjugated bile acids);
- substances increasing mucous membrane permeability (histamine, serotonin);
- substances inducing microcirculatory impairments (endotoxin of Gram-negative bacteria).
8
SAFETY








Pharmacovigilance data for the medicinal product Enterosgel:
Efficacy demonstrated by the clinical studies, beginning from 1982.
International Birth Date (authorization): 29 July 1994. The number of participants in the clinical studies (including post-marketing trials) totals over 21,000 people.  Over 395 studies and publications available.
Over 100,000,000 single doses of the drug are now taken every year in the Russian Federation, CIS and European countries (6,000,000 primary packages). The majority of patients experience pronounced positive effects when using Enterosgel for the therapeutic indications specified in the Prescribing Information.
No serious adverse (unexpected) drug reactions unlisted in the Prescribing Information have been reported to date, which is reflected in the Periodic Safety Update Reports for the medicinal product.
The risk estimate for Enterosgel use is “negligible” (less than 1 case per one million).
Enterosgel has been approved for use in pregnant women and newborn infants.